Acadia planning follow-on

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) proposed a follow-on late Tuesday underwritten by Jefferies; Cowen; JMP Securities; and Needham. Acadia plans to submit an NDA to FDA for pimavanserin around the end of next year. The small molecule serotonin (5-HT2A) receptor inverse agonist is in development to treat Parkinson's disease psychosis (PDP). Shares of Acadia have gained more than 60% since last month, when the company said FDA said existing data, including a single Phase III trial, were sufficient to support the NDA (see BioCentury Extra, April 11). ...